Technology | May 12, 2014

Kalila Medical Gains FDA Clearance For Vado Steerable Sheath for Atrial Fibrillation Procedures

Kalila Medical Vado Steerable Introducer Sheath Atrial Fibrillation Albation EP

May 12, 2014 — Kalila Medical received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Vado steerable introducer sheath used during atrial fibrillation (AF) and other procedures requiring vascular and intracardiac access.

The Vado sheath is the first of its kind steerable sheath that does not require pull wires for tip deflection. Using its patent-protected truVector technology, the Vado steerable sheath is a simple yet innovative solution to creating a high performance, uniquely torqueable steerable sheath that can provide physicians precise control over placement of their ablation catheter.

"Currently available steerable sheaths have a poor torque response, making accurate positioning frustrating and time-consuming," commented Andrea Natale M.D., executive medical director, Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas, and senior medical director, electrophysiology and arrhythmia, California Pacific Medical Center, San Francisco. "I am encouraged by the FDA clearance of a new steerable sheath that may provide better torqueability and tip control, and I look forward to evaluating the Vado in my practice."

AF, the most common cardiac arrhythmia, is an irregular heartbeat that can result in symptoms such as shortness of breath, palpitations and weakness. If untreated, AF can result in a debilitating stroke. Newer approaches to treatment of AF include an endovascular approach using catheter-based ablation to interrupt pathways in the atria and prevent abnormal impulses from propagating. In 2014, it is estimated there will be 350,000 AF ablation procedures worldwide, and it is expected that this market will continue to expand dramatically in the coming years.

The Vado Sheath also received CE mark in December 2013.

For more information: www.kalilamedical.com

Related Content

Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Overlay Init